Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bietaserpine is a small molecule drug and a derivative of reserpine, identified by code names such as DL 152 and N-diethylaminoethyl reserpine. It was investigated as an antihypertensive agent and also exhibited sedative effects. Its mechanism of action involves the inhibition of vesicular monoamine transporters (VMAT1 and VMAT2), similar to its parent compound reserpine. This inhibition leads to the depletion of monoamine neurotransmitters, including norepinephrine, dopamine, and serotonin, from synaptic vesicles. The resulting reduction in sympathetic nervous system activity contributes to its hypotensive effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bietaserpine.